RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @JACCJournals: Patients treated with CAR T cell therapy are at an increased risk for MACE and may benefit from cardiovascular surveillan…
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @Dr_RoohiKhan: #CardioOnc #CART @TomasNeilan @mealomar @Dr_Mike_Fradley @doctorpemm @drbrowncares
RT @Dr_RoohiKhan: #CardioOnc #CART @TomasNeilan @mealomar @Dr_Mike_Fradley @doctorpemm @drbrowncares
RT @Dr_RoohiKhan: #CardioOnc #CART @TomasNeilan @mealomar @Dr_Mike_Fradley @doctorpemm @drbrowncares
#CardioOnc #CART @TomasNeilan @mealomar @Dr_Mike_Fradley @doctorpemm @drbrowncares
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @PennCardsWomen: Fantastic work from our own @PennCVFellows @BenedicteLefeb1 and @PennCardiology #EchoFirst Director @mariellesc1!
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @PennCardsWomen: Fantastic work from our own @PennCVFellows @BenedicteLefeb1 and @PennCardiology #EchoFirst Director @mariellesc1!
RT @PennCardsWomen: Fantastic work from our own @PennCVFellows @BenedicteLefeb1 and @PennCardiology #EchoFirst Director @mariellesc1! https…
RT @PennCardsWomen: Fantastic work from our own @PennCVFellows @BenedicteLefeb1 and @PennCardiology #EchoFirst Director @mariellesc1! https…
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @PennCardsWomen: Fantastic work from our own @PennCVFellows @BenedicteLefeb1 and @PennCardiology #EchoFirst Director @mariellesc1! https…
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
RT @PennCardsWomen: Fantastic work from our own @PennCVFellows @BenedicteLefeb1 and @PennCardiology #EchoFirst Director @mariellesc1!
Fantastic work from our own @PennCVFellows @BenedicteLefeb1 and @PennCardiology #EchoFirst Director @mariellesc1!
RT @JACCJournals: Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD su…
Patients treated with CART19 therapy are at an increased risk for #cardiomyopathy and #AFib, and may benefit from #CVD surveillance. Learn more from #JACCCardioOnc: https://t.co/GvgbNMr2F2 #ImmunoOncology #CardioOnc https://t.co/MNYvtVvAu4
Study objective: to define the occurrence of major adverse cardiovascular events in adult patients treated with CAR T cell therapy & assess relationships among clinical factors, echocardiographic parameters, laboratory values, & cardiovascular outc
RT @tiffchenMD: Congrats @BenedicteLefeb1 et al @PennCardiology! Great work, highlighting role for #cvImaging in monitoring #CardioOnc pati…
RT @tiffchenMD: Congrats @BenedicteLefeb1 et al @PennCardiology! Great work, highlighting role for #cvImaging in monitoring #CardioOnc pati…
RT @tiffchenMD: Congrats @BenedicteLefeb1 et al @PennCardiology! Great work, highlighting role for #cvImaging in monitoring #CardioOnc pati…
RT @tiffchenMD: Congrats @BenedicteLefeb1 et al @PennCardiology! Great work, highlighting role for #cvImaging in monitoring #CardioOnc pati…
RT @tiffchenMD: Congrats @BenedicteLefeb1 et al @PennCardiology! Great work, highlighting role for #cvImaging in monitoring #CardioOnc pati…
RT @JACCJournals: Patients treated with CAR T cell therapy are at an increased risk for MACE and may benefit from cardiovascular surveillan…
RT @tiffchenMD: Congrats @BenedicteLefeb1 et al @PennCardiology! Great work, highlighting role for #cvImaging in monitoring #CardioOnc pati…
Congrats @BenedicteLefeb1 et al @PennCardiology! Great work, highlighting role for #cvImaging in monitoring #CardioOnc patients on CAR-T cell therapy @onco_cardiology @Richardkcheng2 @jelevenson
Study objective: to define the occurrence of major adverse cardiovascular events in adult patients treated with CAR T cell therapy & assess relationships among clinical factors, echocardiographic parameters, laboratory values, & cardiovascular outc
RT @JACCJournals: Patients treated with CAR T cell therapy are at an increased risk for MACE and may benefit from cardiovascular surveillan…
RT @JACCJournals: Patients treated with CAR T cell therapy are at an increased risk for MACE and may benefit from cardiovascular surveillan…
Patients treated with CAR T cell therapy are at an increased risk for MACE and may benefit from cardiovascular surveillance. Read more in #JACCCardioOnc: https://t.co/GvgbNMr2F2 @mariellesc1 @BenedicteLefeb1 https://t.co/CicCB4Rden
Getting closer to figuring out the true cardiac risks of CAR T Cell Therapy | JACC: CardioOncology https://t.co/6bDjuYWGL5